ARRY 797

Drug Profile

ARRY 797

Alternative Names: ARRY-371797; ARRY-797

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Array BioPharma
  • Class Anti-inflammatories; Antineoplastics; Non-opioid analgesics; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Dilated cardiomyopathy
  • No development reported Cancer; Dental pain
  • Discontinued Ankylosing spondylitis; Musculoskeletal pain; Rheumatoid arthritis

Most Recent Events

  • 30 Aug 2016 Adverse events data from a phase II trial in Dilated cardiomyopathy released by Array BioPharma
  • 31 May 2016 Array BioPharma completes a phase II clinical trial for Dilated cardiomyopathy in USA (NCT02057341)
  • 03 May 2016 Array BioPharma plans a pivotal clinical trial for Dilated cardiomyopathy in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top